I heard Omada Health president Sean Duffy on an April 13, 2017 NEJM Catalyst webinar reference the road by which non-pharmacological, integrative diabetes care gained coverage. Duffy, a “high tech high touch” Bay Area entrepreneur, displayed his literally out-of-the-box thinking elsewhere in the webinar when he urged the medical industry to “build a pervasive culture in which in-person visits are a last resort.” Might this interesting executive’s experience offer insights for those who realize that lack of coverage for non-pharmacologic, integrative pain treatment is a massive barrier to human health? I set up an interview.
First, however, I looked into the Diabetes Prevention Program (DPP) that Duffy said provides the data foundation for Omada’s now 50-state program. The 2002 DPP study compared a multi-modal integrative diabetes strategy - diet, physical activity and behavior modification - with the drug Metformin. The integrative arm performed with such success that research was halted early so public benefit could immediately commence.
Read More: www.huffingtonpost.com/entry/omada-healths-duffy-on-integrative-diabetes-coverages_us_57910576e4b0a1917a6e3e06
Via: Huffington Post
Extends Projected Cash Runway through Q3 2019 to Focus on Clinical-Stage Programs and Immuno-Oncology Discovery and Development
REDWOOD CITY, Calif., April 17, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company's randomized 145-patient Phase 2 PINNACLE clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in combination with etoposide plus either cisplatin or carboplatin chemotherapy ("chemotherapy") in previously untreated patients with extensive-stage small cell lung cancer. Results for the combination of tarextumab plus chemotherapy were undifferentiated from those of chemotherapy plus placebo, and therefore the trial did not meet its primary endpoint of progression-free survival or secondary endpoints of overall survival and biomarkers reflective of Notch pathway gene activation.
Via: MedPage Today
Complex aortic arch configurations and internal carotid artery (ICA) tortuosity were bad news for carotid artery stenting, but not endarterectomy, according to an MRI substudy of the International Carotid Stenting Study (ICSS).
Via: Hattiesburg American
Forrest General Hospital became the first hospital in Mississippi to use the transcarotid artery revascularization method of carotid stenting on Feb. 27.
Via: Albuquerque Journal
ALBUQUERQUE, N.M. — Dudley Sue Bock, 75, received the shocking news last July that she had a 70 percent blockage in one of the two arteries that provide blood to her brain.
OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
Anti-TIGIT Demonstrates Potent Anti-Tumor Activity in Preclinical Models
Via: Yahoo! Finance
Outset Medical, a commercial-stage company delivering new technology into the $13 billion global dialysis market, today announced the appointment of Gus Castello as the company’s chief operating officer.
Via: The Hill
BY SEAN DUFFY, OPINION CONTRIBUTOR
OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical immuno-oncology and anti-cancer stem cell therapeutic candidates in a total of six presentations at the upcoming American Association for Cancer Research (AACR) Meeting to be held April 1-5, 2017 in Washington, DC.